HC Wainwright Lowers Earnings Estimates for Bausch + Lomb

Bausch + Lomb Corporation (NYSE:BLCO) – Equities research analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for shares of Bausch + Lomb in a note issued to investors on Monday, August 3rd. HC Wainwright analyst Y. Chen now expects that the company will earn $0.17 per share for the quarter, down from their previous forecast of $0.21. HC Wainwright has a “Buy” rating and a $21.00 price objective on the stock. The consensus estimate for Bausch + Lomb’s current full-year earnings is $0.81 per share. HC Wainwright also issued estimates for Bausch + Lomb’s Q4 2026 earnings at $0.28 EPS and FY2026 earnings at $0.68 EPS.

BLCO has been the topic of a number of other reports. Wall Street Zen upgraded Bausch + Lomb from a “hold” rating to a “buy” rating in a research note on Saturday, April 18th. Weiss Ratings upgraded shares of Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 24th. Citigroup boosted their price target on shares of Bausch + Lomb from $19.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. UBS Group initiated coverage on shares of Bausch + Lomb in a report on Thursday, July 30th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft set a $16.00 price objective on shares of Bausch + Lomb in a research note on Thursday, April 30th. Five research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $18.75.

Bausch + Lomb Price Performance

Shares of BLCO stock opened at $16.66 on Wednesday. Bausch + Lomb has a 12 month low of $13.53 and a 12 month high of $18.92. The company has a market capitalization of $5.95 billion, a P/E ratio of -34.70, a P/E/G ratio of 0.52 and a beta of 0.56. The stock has a 50 day moving average of $15.96 and a two-hundred day moving average of $16.41. The company has a current ratio of 1.55, a quick ratio of 1.02 and a debt-to-equity ratio of 0.79.

Hedge Funds Weigh In On Bausch + Lomb

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Glenview Capital Management LLC raised its stake in Bausch + Lomb by 210.8% during the second quarter. Glenview Capital Management LLC now owns 1,553,855 shares of the company’s stock worth $20,216,000 after acquiring an additional 1,053,855 shares in the last quarter. Davidson Kempner Capital Management LP acquired a new stake in shares of Bausch + Lomb during the 3rd quarter worth about $14,776,000. Woodline Partners LP lifted its holdings in Bausch + Lomb by 175.3% during the 3rd quarter. Woodline Partners LP now owns 861,053 shares of the company’s stock valued at $12,976,000 after purchasing an additional 548,230 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Bausch + Lomb by 428.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 299,671 shares of the company’s stock valued at $4,345,000 after purchasing an additional 242,993 shares during the last quarter. Finally, Whitebox Advisors LLC boosted its position in Bausch + Lomb by 15.8% in the first quarter. Whitebox Advisors LLC now owns 1,101,854 shares of the company’s stock valued at $17,519,000 after buying an additional 150,641 shares in the last quarter. Institutional investors own 11.07% of the company’s stock.

Bausch + Lomb News Summary

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: HC Wainwright raised its price target to $21 from $20 and maintained a “Buy” rating, implying substantial potential appreciation from recent trading levels. The firm’s target reflects confidence in Bausch + Lomb’s longer-term prospects. Benzinga report on HC Wainwright price-target increase
• Positive Sentiment: The analyst increased its 2027 EPS forecasts for the first and second quarters to $0.12 and $0.25, respectively, from $0.07 and $0.22, suggesting some expected improvement later in the forecast period.
• Neutral Sentiment: HC Wainwright continues to project FY2027 EPS of $0.89, compared with the current-year consensus estimate of $0.81, indicating expected earnings growth despite the revisions.
• Negative Sentiment: The main pressure comes from broad reductions to earnings estimates. FY2026 EPS was cut to $0.68 from $0.83, while Q3 and Q4 2026 estimates fell to $0.17 and $0.28 from $0.21 and $0.34. The FY2026 forecast is now below the $0.81 consensus estimate, raising concerns about near-term profitability. HC Wainwright forecasts for Bausch + Lomb
• Negative Sentiment: HC Wainwright also reduced its FY2027 EPS forecast to $0.89 from $0.93 and lowered Q3 and Q4 2027 estimates, indicating that the earnings outlook remains mixed beyond 2026.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.